J
J. Bladé
Researcher at University of Barcelona
Publications - 105
Citations - 11223
J. Bladé is an academic researcher from University of Barcelona. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 44, co-authored 105 publications receiving 10227 citations.
Papers
More filters
Journal ArticleDOI
International uniform response criteria for multiple myeloma
Brian G.M. Durie,J L Harousseau,Jesús F. San Miguel,J. Bladé,Bart Barlogie,Kenneth C. Anderson,Morie A. Gertz,Meletios A. Dimopoulos,Johan Westin,Pieter Sonneveld,Heinz Ludwig,G. Gahrton,Meral Beksac,John Crowley,Andrew Belch,M. Boccadaro,Ingemar Turesson,Douglas E. Joshua,David H. Vesole,Robert A. Kyle,Raymond Alexanian,Guido Tricot,M. Attal,Giampaolo Merlini,R. L. Powles,Paul G. Richardson,K. Shimizu,Patrizia Tosi,Gareth J. Morgan,S V Rajkumar +29 more
TL;DR: The European Group for Blood and Bone Marrow Transplant/International Bone Marrows Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system to adequately assess clinical outcomes in myeloma.
Journal ArticleDOI
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Antonio Palumbo,S V Rajkumar,Meletios A. Dimopoulos,Paul G. Richardson,J F San Miguel,Bart Barlogie,J L Harousseau,Jeffrey A. Zonder,Michele Cavo,Maurizio Zangari,M. Attal,Andrew Belch,S. Knop,Douglas E. Joshua,Orhan Sezer,Heinz Ludwig,David H. Vesole,J. Bladé,Robert A. Kyle,Jan Westin,Donna M. Weber,Sara Bringhen,Ruben Niesvizky,Anders Waage,M. von Lilienfeld-Toal,Sagar Lonial,Gareth J. Morgan,Robert Z. Orlowski,Kazuyuki Shimizu,KC Anderson,Mario Boccadoro,Brian G.M. Durie,Pieter Sonneveld,Mohamad A. Hussein +33 more
TL;DR: This manuscript summarizes the available evidence and recommends a prophylaxis strategy according to a risk-assessment model for venous thromboembolism (VTE), and recommends low-molecular-weight heparin (LMWH), warfarin or aspirin.
Journal ArticleDOI
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
Angela Dispenzieri,Robert A. Kyle,Giampaolo Merlini,Jesús F. San Miguel,Heinz Ludwig,Roman Hájek,Antonio Palumbo,Sundar Jagannath,J. Bladé,Sagar Lonial,Meletios A. Dimopoulos,Raymond L. Comenzo,H. Einsele,Bart Barlogie,KC Anderson,Morie A. Gertz,J L Harousseau,M. Attal,Patrizia Tosi,Pieter Sonneveld,Mario Boccadoro,Gareth J. Morgan,Paul G. Richardson,O. Sezer,Maria-Victoria Mateos,Michele Cavo,Douglas E. Joshua,Ingemar Turesson,Wenming Chen,K. Shimizu,R. L. Powles,S V Rajkumar,Brian G.M. Durie +32 more
TL;DR: Consensus guidelines for the use of the serum immunoglobulin-free light chain assay are provided, in the diagnosis and management of clonal PCD.
Journal ArticleDOI
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Robert A. Kyle,Brian G.M. Durie,S V Rajkumar,Ola Landgren,J. Bladé,Giampaolo Merlini,N Kröger,H. Einsele,David H. Vesole,Meletios A. Dimopoulos,J F San Miguel,Hervé Avet-Loiseau,Roman Hájek,Wenming Chen,Kenneth C. Anderson,Heinz Ludwig,Pieter Sonneveld,Santiago Pavlovsky,Antonio Palumbo,Paul G. Richardson,Bart Barlogie,P R Greipp,Robert Vescio,Ingemar Turesson,Jan Westin,Mario Boccadoro +25 more
TL;DR: Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of residents of Olmsted County, Minnesota, 50 years of age or older and is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio.
Journal ArticleDOI
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji Kumar,Je-Hwan Lee,J. J. Lahuerta,Gareth J. Morgan,Paul G. Richardson,John Crowley,Jeffrey Haessler,John Feather,Antje Hoering,Philippe Moreau,Xavier Leleu,C. Hulin,S. K. Klein,Pieter Sonneveld,David S. Siegel,J. Bladé,H. Goldschmidt,Sundar Jagannath,Jesús F. San Miguel,Robert Z. Orlowski,Antonio Palumbo,O. Sezer,S V Rajkumar,Brian G.M. Durie +23 more
TL;DR: The median overall survival and event-free survival from T0 were 9 and 5 months, respectively, which confirms the poor outcome, once patients become refractory to current treatments.